ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 662,30
0,00%
Dow Jones
39 112,16
-0,76%
DAX
18 177,62
-0,90%
Brent Oil
84,75
0,67%
Bitcoin
61 522,27
-0,47%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NLS Pharmaceutics Ltd (NLSP)

  7. NLS Pharmaceutics Ltd (NLSP) Actualités

NLSP

NLS Pharmaceutics (NLSP)

NLS Pharmaceutics Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NLSP
DateHeureSourceTitreSymboleSociété
11/03/202421h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
14/06/202314h38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NLSPNLS Pharmaceutics Ltd
05/05/202322h37Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
01/05/202322h31Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
24/02/202313h56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NLSPNLS Pharmaceutics Ltd
14/02/202312h10Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
23/01/202312h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:NLSPNLS Pharmaceutics Ltd
13/01/202322h03Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:NLSPNLS Pharmaceutics Ltd
21/12/202222h03Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:NLSPNLS Pharmaceutics Ltd
16/12/202222h58Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
10/06/202222h44Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:NLSPNLS Pharmaceutics Ltd
02/06/202218h15TipRanksBrookline Capital Markets Thinks NLS Pharmaceutics’ Stock is Going to RecoverNASDAQ:NLSPNLS Pharmaceutics Ltd
04/05/202220h25TipRanksBrookline Capital Markets Sticks to Their Buy Rating for NLS Pharmaceutics (NLSP)NASDAQ:NLSPNLS Pharmaceutics Ltd
14/04/202222h49Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NLSPNLS Pharmaceutics Ltd
13/04/202214h18Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:NLSPNLS Pharmaceutics Ltd
17/03/202215h36TipRanksMaxim Group Thinks NLS Pharmaceutics’ Stock is Going to RecoverNASDAQ:NLSPNLS Pharmaceutics Ltd
01/11/202113h31Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
02/06/202114h00PR Newswire (US)NLS Pharmaceutics to Present at the LD Micro Virtual Invitational Conference on June 10, 2021NASDAQ:NLSPNLS Pharmaceutics Ltd
28/05/202114h15PR Newswire (US)NLS Pharmaceutics to Present at The MicroCap Rodeo 2021 Summer Solstice: Best Ideas from the Buyside Conference on June 1NASDAQ:NLSPNLS Pharmaceutics Ltd
27/05/202123h29Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:NLSPNLS Pharmaceutics Ltd
18/05/202114h15PR Newswire (US)NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation for Treating NarcolepsyNASDAQ:NLSPNLS Pharmaceutics Ltd
05/04/202114h30PR Newswire (US)NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating OfficerNASDAQ:NLSPNLS Pharmaceutics Ltd
29/03/202114h30PR Newswire (US)NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazind...NASDAQ:NLSPNLS Pharmaceutics Ltd
12/03/202114h00PR Newswire (US)NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)NASDAQ:NLSPNLS Pharmaceutics Ltd
25/02/202115h00PR Newswire (US)NLS Pharmaceutics to Participate in Upcoming Investor ConferencesNASDAQ:NLSPNLS Pharmaceutics Ltd
02/02/202122h00PR Newswire (US)NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public OfferingNASDAQ:NLSPNLS Pharmaceutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NLSP

Dernières Valeurs Consultées

NASDAQ
TZAC
Tenzing Acquisition
LSE
BJ03
Hsbc Bk.23
TG
RKCA
RaiffeisenNachhaltigkeit...
TG
SIA1
Singapore Airlines
NASDAQ
KSCP
Knightscope
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés